mRNA lipid nanoparticles in CAR-T therapy: a novel strategy to improve efficacy
- 16 May 2025
- journal article
- review article
- Published by IOP Publishing in Nanotechnology
- Vol. 36 (22) , 222003
Abstract
Chimeric antigen receptor T cells (CAR-T) immunotherapy has achieved remarkable progress in the treatment of hematological malignancies. However, it encounters challenges including complex manufacturing processes, high cost, and safety issues. Lipid nanoparticle (LNP) technology, as an advanced gene delivery platform, offers significant advancements to CAR-T therapy through its high efficiency, low immunogenicity, and safety. LNP enable in vivo production of CAR-T cells, thereby improving delivery efficiency, reducing the risks of immunogenicity and insertional mutations, simplifying the production process and reducing costs. The scalability and rapid optimization ability of LNP position them as promising candidates for CAR-T cell production. LNP technology is expected to further promote the development of CAR-T immunotherapy and provide safer and more economical treatment options. Therefore, this paper aims to provide a comprehensive and systematic review of the application of LNP in CAR-T therapy. In this review, we initially outline the fundamental design, process, and current challenges of CAR-T therapy. Subsequently, we present the characteristics of LNP, their advantages as a gene delivery vectors, and how they improve the efficacy of CAR-T therapy. Finally, we summarize the current research landscape of LNP applications in CAR-T therapy. This includes enhancing in vitro transfection of T cells, programming T cells in situ, facilitating T-cell activation, alleviating the side effects of CAR-T therapy, and combining CAR-T therapy with other immunotherapies. These advancements will aid in the design of mRNA delivery systems based on LNP, thereby promoting the development of CAR-T therapy.Keywords
Funding Information
- Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0500800)
- Natural Science Foundation of Tianjin Municipality (22JCQNJC00070)
- China Postdoctoral Science Foundation (2022M720502)
- Fundamental Research Funds for the Central Universities (2019PT320028)
- Youth Talent Support Program of the China Association for Science and Technology (2024-2026QNRC001)
- National Natural Science Foundation of China (32401129)
- State Key Laboratory of Advanced Medical Materials and Devices Research Grant (YGSKL-JYY-2024-JK03)
- CAMS Innovation Fund for Medical Sciences (2021-I2M-1-058)
- CAMS Union Young Scholars Support Program (2022051)
This publication has 116 references indexed in Scilit:
- A Versatile Strategy to Transform Cationic Polymers for Efficient and Organ‐Selective mRNA DeliveryAngewandte Chemie International Edition, 2025
- Identification and characterisation of novel CAR‐T cells to target IL13Rα2 positive human glioma in vitro and in vivoClinical and Translational Medicine, 2024
- Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer ImmunotherapyAdvanced Materials, 2024
- Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte EngineeringAdvanced Functional Materials, 2024
- In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic TropismSmall, 2023
- Spleen SORT LNP Generated in situ CAR T Cells Extend Survival in a Mouse Model of Lymphoreplete B Cell LymphomaAngewandte Chemie International Edition, 2023
- Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell EngineeringAdvanced Healthcare Materials, 2023
- The role of lipid components in lipid nanoparticles for vaccines and gene therapyAdvanced Drug Delivery Reviews, 2022
- Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics PerspectiveAdvanced Functional Materials, 2022
- Side-effect management of chimeric antigen receptor (CAR) T-cell therapyAnnals of Oncology, 2021